We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Alethia Announces Issuance of its First Therapeutic Target Patent Emanating from its Proprietary Target Discovery Platform

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Alethia Announces Issuance of its First Therapeutic Target Patent Emanating from its Proprietary Target Discovery Platform"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Alethia Biotherapeutics Inc., has announced the issuance of US patent number 7,947,436 entitled "Polynucleotide and Polypeptide Sequences Involved in the Process of Bone Remodeling". This key patent provides protection for identification of Tsp50 inhibitors of osteoclast differentiation.

Mr. Yves Cornellier, President & CEO of Alethia commented, "This first target patent represents a significant milestone for the Company as it validates the discovery capabilities and the strategy of the organization to focus on the development of monoclonal antibodies against novel proprietary targets. This patent is the first of a series of patents for protection of other novel targets to be issued in the coming months."

Alethia used its proprietary subtractive cloning technology, called STAR, to discover new mRNA sequences that are expressed in differentiating osteoclasts, the cells responsible for bone resorption.

Osteoclasts, which normally participate in bone remodeling, a process that occurs naturally throughout life to maintain skeletal structure, are cells that can become over-active in diseases where severe bone loss occurs.

Work performed at Alethia has demonstrated an important functional role for Tsp50 in differentiating osteoclasts and inhibitors of this protein, such as monoclonal antibodies, lead to impairment of their function.

Dr. Mario Filion, Chief Scientific Officer of Alethia commented, "This target certainly offers a new promising avenue to the development of new bone anti-resorptives with improved specificity and reflects the innovative research potential of the organization".